Sign In
Buy IONS
$56.75
-1.50 (-2.58%)
At Close: Jul 13, 2026
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
12:25pm, Monday, 13'th Jul 2026
When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes evenly across the board. The fallout often reveals undeniable fundamental truths about single-asset e
IONS Investor Alert: Levi & Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS)
10:00am, Monday, 13'th Jul 2026
NEW YORK--(BUSINESS WIRE)--Shares of Ionis Pharmaceuticals fell more than 20% in the early trading on July 9, 2026, after the Company announced that its late-stage Phase-3 CARDIO-TTRansform trial, par
Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome
07:00am, Monday, 13'th Jul 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the Phase 1-2 ASCEND study of ION337, an investigational RNA-
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up
03:37pm, Friday, 10'th Jul 2026
Shares of Ionis Pharmaceuticals (NASDAQ:IONS | IONS Price Prediction) are down 9% intraday, changing hands near $58.30 after opening the session at $64.27.
Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain
11:30am, Friday, 10'th Jul 2026
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and partner AstraZeneca Plc (NYSE:AZN) said on Thursday that their Phase 3 CARDIO-TTRansform study of eplontersen for transthyretin-mediated amyloid cardiomyop
IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals
09:00am, Friday, 10'th Jul 2026
/PRNewswire/ -- Shares of Ionis Pharmaceuticals (NASDAQ: IONS) dropped more than 20% pre-market on July 9, 2026, after the Company announced that its
Ionis Pharmaceuticals told investors its CARDIO-TTRansform program was on track to deliver landmark data -- then the Phase-3 trial missed its primary endpoint. Levi & Korsinsky is investigating.
AstraZeneca And Ionis Pharma Rocked By Heart Disease Fail: Why You Shouldn't Panic
03:58pm, Thursday, 09'th Jul 2026
AstraZeneca PLC shares fell >6% after Wainua (eplontersen) failed its Phase 3 ATTR-CM trial, missing a major revenue opportunity. The stock of Ionis Pharmaceuticals, Inc., developer of eplontersen and
Ionis, AstraZeneca Pivotal Heart Disease Drug Flunks
08:09am, Thursday, 09'th Jul 2026
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and partner AstraZeneca Plc (NYSE:AZN) on Thursday said their Phase 3 CARDIO-TTRansform study of eplontersen for transthyretin-mediated amyloid cardiomyopathy
AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.
07:38am, Thursday, 09'th Jul 2026
AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing drug, Wainua.
AstraZeneca-Ionis drug fails to meet main goal in late-stage heart disease trial
02:12am, Thursday, 09'th Jul 2026
AstraZeneca said on Thursday that its drug Wainua, made in partnership with Ionis , failed to meet the main goal of reducing cardiovascular deaths and recurring heart
Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy
02:00am, Thursday, 09'th Jul 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and partner AstraZeneca today announced that the CARDIO-TTRansform Phase 3 trial for eplontersen in patients with transthy
IONS Completes Enrollment in Pivotal Cohort of Angelman Syndrome Study
01:31pm, Tuesday, 07'th Jul 2026
Ionis completes enrollment in the pivotal pediatric cohort of its phase III REVEAL study, advancing obudanersen toward potential regulatory submissions.
Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome
07:00am, Monday, 06'th Jul 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has completed enrollment in the pivotal cohort (Cohort 1) of the global Phase 3 REVEAL study evalu
IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati
11:45am, Friday, 26'th Jun 2026
Ionis grants Recordati ex-U.S. rights to zilganersen for Alexander disease while retaining U.S. commercialization and securing upfront and royalty payments.
